NZ715459A - A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same - Google Patents

A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same

Info

Publication number
NZ715459A
NZ715459A NZ715459A NZ71545913A NZ715459A NZ 715459 A NZ715459 A NZ 715459A NZ 715459 A NZ715459 A NZ 715459A NZ 71545913 A NZ71545913 A NZ 71545913A NZ 715459 A NZ715459 A NZ 715459A
Authority
NZ
New Zealand
Prior art keywords
same
hyperbarically
methods
immunogenic compositions
microorganism
Prior art date
Application number
NZ715459A
Other languages
English (en)
Inventor
Nicolas Pierre Yves Carboulec
Gildas Merian
RENé LABATUT
Lionel Gerentes
Original Assignee
Top Ind S A S
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Top Ind S A S, Merial Inc filed Critical Top Ind S A S
Publication of NZ715459A publication Critical patent/NZ715459A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/10—Preservation of foods or foodstuffs, in general by treatment with pressure variation, shock, acceleration or shear stress
    • A23B2/103—Preservation of foods or foodstuffs, in general by treatment with pressure variation, shock, acceleration or shear stress using sub- or super-atmospheric pressures, or pressure variations transmitted by a liquid or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01041—Sterol 24-C-methyltransferasee (2.1.1.41)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Sustainable Development (AREA)
NZ715459A 2012-08-30 2013-08-30 A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same NZ715459A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261694968P 2012-08-30 2012-08-30
US201361830425P 2013-06-03 2013-06-03
NZ705790A NZ705790A (en) 2012-08-30 2013-08-30 Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins

Publications (1)

Publication Number Publication Date
NZ715459A true NZ715459A (en) 2017-05-26

Family

ID=49162270

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ715459A NZ715459A (en) 2012-08-30 2013-08-30 A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
NZ705790A NZ705790A (en) 2012-08-30 2013-08-30 Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
NZ706288A NZ706288A (en) 2012-08-30 2013-08-30 Expression of chimeric ksac protein and method of producing soluble proteins by high pressure

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ705790A NZ705790A (en) 2012-08-30 2013-08-30 Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
NZ706288A NZ706288A (en) 2012-08-30 2013-08-30 Expression of chimeric ksac protein and method of producing soluble proteins by high pressure

Country Status (18)

Country Link
US (3) US9169302B2 (enExample)
EP (2) EP2890392B1 (enExample)
JP (2) JP6405308B2 (enExample)
KR (1) KR102208844B1 (enExample)
CN (3) CN104717976A (enExample)
AP (1) AP2015008331A0 (enExample)
AU (4) AU2013308623B2 (enExample)
BR (1) BR112015004463B8 (enExample)
CA (2) CA2883303A1 (enExample)
EA (1) EA031988B1 (enExample)
ES (1) ES2744709T3 (enExample)
HK (1) HK1211874A1 (enExample)
MD (1) MD4608C1 (enExample)
MX (3) MX358782B (enExample)
NZ (3) NZ715459A (enExample)
PH (1) PH12015500700B1 (enExample)
RU (1) RU2647568C2 (enExample)
WO (2) WO2014036349A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968749B2 (en) * 2006-07-21 2015-03-03 Universidade Federal De Minas Gerais—Ufmg Vaccine composition and immunization method
ZA201501696B (en) 2012-08-30 2016-01-27 Merial Ltd Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
MX358782B (es) 2012-08-30 2018-09-04 Merial Inc Expresión de proteina ksac quimérica y método para producir proteínas solubles mediante alta presión.
EP2978447B1 (en) * 2013-03-28 2019-05-08 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
CN104758944B (zh) 2015-04-02 2017-11-28 中国科学院过程工程研究所 一种疫苗制剂及其制备方法和用途
JP2018082987A (ja) * 2016-11-25 2018-05-31 株式会社日立製作所 ウイルス不活化方法及びウイルス不活化装置
JP2020152644A (ja) * 2019-03-18 2020-09-24 国立大学法人愛媛大学 Ｖｎａｒのリフォールディング方法およびｖｎａｒの製造方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN112120012B (zh) * 2020-09-30 2022-03-22 广东康盾创新产业集团股份公司 一种car-t细胞冻存方法
BR102021000794A2 (pt) * 2021-01-15 2022-07-26 Fundação Oswaldo Cruz Proteína quimérica, kit, método para diagnóstico de leishmaniose, uso de uma proteína quimérica, composição vacinal contra leishmaniose visceral, e, uso de uma composição vacinal

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
JP2743177B2 (ja) * 1987-04-24 1998-04-22 財団法人阪大微生物病研究会 百日咳菌の培養方法、及び百日咳トキソイドとその混合ワクチン
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
FR2771011B1 (fr) 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
AU4975699A (en) 1998-07-09 2000-02-01 University Technology Corporation High pressure refolding of protein aggregates and inclusion bodies
EP1180945A1 (en) 1999-05-28 2002-02-27 Universite Laval Inactivation of food spoilage and pathogenic microorganisms by dynamic high pressure
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
AU780979B2 (en) 1999-09-25 2005-04-28 Coley Pharmaceutical Gmbh Immunostimulatory nucleic acids
US7615617B2 (en) 1999-10-25 2009-11-10 University Of Delaware Use of hydrostatic pressure to inhibit and reverse protein aggregation and facilitate protein refolding
AU2002246493A1 (en) 2000-08-10 2002-07-30 Boston Biomedica, Inc. Pressure cycling inactivation of pathogens in biological materials used for therapeutics or vaccines
US6635223B2 (en) 2000-10-25 2003-10-21 Andreas Maerz Method for inactivating micro-organisms using high pressure processing
DE60133426T2 (de) * 2000-10-31 2008-11-13 BaroFold, Inc., Boulder Verbesserter zerfall und rückfaltung von proteinen mittels hohen drucks
AU2003245416A1 (en) 2002-06-07 2004-04-30 University Of Florida Endodontic files made using bulk metallic glasses
SE525457C2 (sv) * 2002-06-24 2005-02-22 Flow Holdings Sagl Förfarande för åstadkommande av en tryckändring mellan två trycktillstånd, högtryckspressanordning samt användning av förfarande eller högtryckspressanordning
WO2005044301A2 (en) * 2003-11-05 2005-05-19 C.B.F. Leti, S.L. Unipersonal Use of specific histones for the treatment of parasitic diseases
US7993580B2 (en) 2004-08-24 2011-08-09 Baxter International Inc. Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors
AU2006318435A1 (en) 2005-11-21 2007-05-31 Barofold, Inc. Devices and methods for high-pressure refolding of proteins
CN200945252Y (zh) * 2006-09-01 2007-09-12 天津市华泰森淼生物工程技术有限公司 手动开启式小型超高压生物处理设备
US20080161242A1 (en) 2006-09-15 2008-07-03 Randolph Theodore W High pressure treatment of proteins for reduced immunogenicity
US7829681B2 (en) 2007-04-05 2010-11-09 Barofold Inc. High-pressure inclusion body solubilization and protease clipping of recombinant fusion proteins
WO2008124134A2 (en) 2007-04-05 2008-10-16 Barofold, Inc. High-pressure refolding of proteins in the presence of binding partners
WO2009045553A1 (en) 2007-10-05 2009-04-09 Barofold, Inc. High pressure treatment of aggregated interferons
AU2008348022B2 (en) * 2007-12-21 2015-03-05 Zoetis Services Llc Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins
BRPI0800357A2 (pt) 2008-03-10 2009-10-27 Fundacao Oswaldo Cruz método para produção de uma vacina estabilizada
EP2283035B1 (en) 2008-05-08 2015-07-29 Merial Limited Leishmania vaccine using sand fly salivary immunogen
US8410258B2 (en) * 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
EP2300051B1 (en) 2008-05-21 2014-11-12 Infectious Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
WO2009155102A2 (en) 2008-05-30 2009-12-23 Barofold, Inc. Method for derivatization of proteins using hydrostatic pressure
US20110070219A1 (en) 2009-04-27 2011-03-24 Seefeldt Matthew B High pressure protein crystallization
CA2787320A1 (en) 2010-02-01 2011-08-04 Avure Technologies Ab High-pressure arrangement with locking element preventing rotation of load basket
CN201781934U (zh) * 2010-04-14 2011-04-06 中国农业大学 一种小型框架自动式超高压设备
EP2600843B9 (en) 2010-07-19 2020-03-11 Pressure BioSciences, Inc. Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy
MX358782B (es) * 2012-08-30 2018-09-04 Merial Inc Expresión de proteina ksac quimérica y método para producir proteínas solubles mediante alta presión.
ZA201501696B (en) * 2012-08-30 2016-01-27 Merial Ltd Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins

Also Published As

Publication number Publication date
MX2015002701A (es) 2015-12-01
CA2883303A1 (en) 2014-03-06
US20170081372A1 (en) 2017-03-23
MD4608B1 (ro) 2018-12-31
KR102208844B1 (ko) 2021-01-27
AU2013308627B2 (en) 2016-10-27
MX2015002699A (es) 2015-12-01
AU2017200301A1 (en) 2017-02-16
PH12015500700A1 (en) 2015-05-25
AU2017201724A1 (en) 2017-03-30
BR112015004463A2 (pt) 2017-08-08
CN104768577A (zh) 2015-07-08
MX381717B (es) 2025-03-13
AU2013308623B2 (en) 2017-03-02
JP6438396B2 (ja) 2018-12-12
NZ706288A (en) 2016-06-24
ES2744709T3 (es) 2020-02-26
EA201500275A1 (ru) 2015-07-30
CN104768577B (zh) 2020-06-09
HK1211873A1 (en) 2016-06-03
AU2017201724B2 (en) 2019-01-17
WO2014036345A3 (en) 2014-06-26
EP2890393A2 (en) 2015-07-08
CA2883296A1 (en) 2014-03-06
MD20150031A2 (ro) 2015-10-31
US20140065187A1 (en) 2014-03-06
EA031988B1 (ru) 2019-03-29
US9315553B2 (en) 2016-04-19
US10364274B2 (en) 2019-07-30
PH12015500700B1 (en) 2018-11-28
WO2014036345A2 (en) 2014-03-06
EP2890392B1 (en) 2019-04-17
BR112015004463B8 (pt) 2022-06-28
AU2013308627A1 (en) 2015-04-09
MD4608C1 (ro) 2019-07-31
BR112015004463B1 (pt) 2021-08-24
HK1211874A1 (zh) 2016-06-03
EP2890392A1 (en) 2015-07-08
RU2647568C2 (ru) 2018-03-16
KR20150063403A (ko) 2015-06-09
RU2015111255A (ru) 2016-10-20
NZ705790A (en) 2016-06-24
CN108578679A (zh) 2018-09-28
AU2013308623A1 (en) 2015-04-02
US20140072594A1 (en) 2014-03-13
WO2014036349A1 (en) 2014-03-06
JP6405308B2 (ja) 2018-10-17
MX2021004478A (es) 2021-06-04
MX358782B (es) 2018-09-04
CN104717976A (zh) 2015-06-17
AP2015008331A0 (en) 2015-03-31
JP2015528466A (ja) 2015-09-28
JP2015529462A (ja) 2015-10-08
US9169302B2 (en) 2015-10-27

Similar Documents

Publication Publication Date Title
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
EP4494650A3 (en) Vaccine compositions having improved stability and immunogenicity
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
PH12020500101A1 (en) Novel muscosal adjuvants and delivery systems
WO2013054199A3 (en) Cmv antigens and uses thereof
MX343048B (es) Oligodesoxinucleotidos inmunoestimulantes.
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
NZ603863A (en) Concentration and lyophilization of influenza vaccine antigens
AR091582A1 (es) Vacunas atenuadas contra streptococcus suis y metodos de elaboracion y uso de las mismas
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
MX346596B (es) Oligodesoxinucleotidos inmunoestimuladores.
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
WO2015051371A3 (en) Haemophilus parasuis vaccine serovar type four
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
HK1211980A1 (en) Multifunctional oral vaccine based on chromosome recombineering
MX2022013912A (es) Procedimientos novedosos para inducir una respuesta inmunitaria.
GB2515222A (en) Use of flagellin as a vaccine
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.
MX367780B (es) Complejo inmunogénico para vacunación y método de obtención.
WO2013173256A3 (en) New and improved influenza vaccines
EP2929894A4 (en) VACCINE ADJUVANS, PREPARATION AND VACCINES THEREOF
WO2012103444A3 (en) Immunogenic compositions and reagents for preparing
IL234629B (en) An immunogenic preparation for use in a method for increasing a protective immune response against Haemophilus influenzae infection and a process for its preparation
HK1224187A1 (zh) 针对药物成瘾的疫苗组合物

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 AUG 2019 BY COMPUTER PACKAGES INC

Effective date: 20180731

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 AUG 2020 BY COMPUTER PACKAGES INC

Effective date: 20190820

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 AUG 2021 BY COMPUTER PACKAGES INC

Effective date: 20200731

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 AUG 2022 BY DENNEMEYER + CO.

Effective date: 20210823

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 AUG 2023 BY DENNEMEYER+CO

Effective date: 20220822

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 AUG 2024 BY DENNEMEYER + CO.

Effective date: 20230822

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 AUG 2025 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20240819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 AUG 2026 BY DENNEMEYER AND CO. SARL

Effective date: 20250818